Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.47 |
| ▸ | ITK | Q08881 | 3/20 | 0.36 |
| ▸ | PLK4 | O00444 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | FES | P07332 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | FRK | P42685 | 2/20 | 0.36 |
| ▸ | CLK2 | P49760 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.36 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.36 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.36 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12633999 | 0.91 | BRAF (0.42) | BRAFITKPLK4AURKAMAP4K4 | |
| SCHEMBL413743 | 0.91 | BRAF (0.44) | BRAFITKPLK4AURKAMAP4K4 | |
| SCHEMBL414042 | 0.89 | BRAF (0.42) | BRAFITKPLK4AURKAMAP4K4 | |
| SCHEMBL412497 | 0.89 | MTNR1B (0.39) | BRAFITKMAP4K4FESFGFR1 | |
| SCHEMBL858655 | 0.87 | BRAF (0.45) | BRAFITKPLK4AURKAMAP4K4 | |
| SCHEMBL858696 | 0.87 | BRAF (0.42) | BRAFITKPLK4AURKAMAP4K4 | |
| SCHEMBL1085675 | 0.84 | BRAF (0.34) | BRAFITKLIMK1ROCK2BTK | |
| SCHEMBL414796 | 0.83 | BRAF (0.44) | BRAFMAP4K4FLT1KDRCLK2 | |
| SCHEMBL414898 | 0.83 | NEK1 (0.47) | DYRK1AAXLKITCLK1RIPK1 | |
| SCHEMBL298117 | 0.82 | BRAF (0.40) | BRAFITKPLK4AURKAMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | disclosed |
| EP-2516438-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | BRAF 1/4885ITK 50/4885PLK4 550/4885 |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | BRAF 1/4885ITK 50/4885PLK4 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.